Inflammation After Colon Cancer Surgery Tied to Worse Outcomes
Elevated levels of inflammatory biomarkers are associated with worse outcomes for patients with stage III colon cancer, a study suggests.
Elevated levels of inflammatory biomarkers are associated with worse outcomes for patients with stage III colon cancer, a study suggests.
Benefits include histopathologic downstaging, fewer incomplete resections, and better two-year disease control.
AIAC group had lower adenoma and polyp detection rates; lower median number of adenomas, polyps detected per colonoscopy.
Neoadjuvant nivolumab and ipilimumab produced an “unprecedented” major pathologic response rate in the NICHE-2 study, according to the lead study author.
Overall, adjuvant chemotherapy does not appear to increase the risk of second cancers for patients with stage III-IV colon cancer.
Patients on dialysis die from cancer at twice the rate as those of the same age and sex in the general population, a study found.
The decrease in prostate cancer screening rates was the smallest among 5 cancers studied.
Celecoxib failed to reduce the risk of recurrence in patients with colon cancer.
An update on the available cancer screening guidelines, benefits/limitations, and risks for cervical, breast, prostate, colon, and lung cancers.
Results suggest universal health care could reduce racial disparities in survival.